These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 37872778)

  • 1. Tracking the cellular immune response from early premalignancy to active multiple myeloma in a new model.
    Jadhav SS; Luboshits G; Bogen B; Firer MA
    Eur J Immunol; 2024 Jan; 54(1):e2350627. PubMed ID: 37872778
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Early alterations in stem-like/resident T cells, innate and myeloid cells in the bone marrow in preneoplastic gammopathy.
    Bailur JK; McCachren SS; Doxie DB; Shrestha M; Pendleton K; Nooka AK; Neparidze N; Parker TL; Bar N; Kaufman JL; Hofmeister CC; Boise LH; Lonial S; Kemp ML; Dhodapkar KM; Dhodapkar MV
    JCI Insight; 2019 Apr; 5(11):. PubMed ID: 31013254
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A reversible defect in natural killer T cell function characterizes the progression of premalignant to malignant multiple myeloma.
    Dhodapkar MV; Geller MD; Chang DH; Shimizu K; Fujii S; Dhodapkar KM; Krasovsky J
    J Exp Med; 2003 Jun; 197(12):1667-76. PubMed ID: 12796469
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Regulation of antigen-specific T cell infiltration and spatial architecture in multiple myeloma and premalignancy.
    Robinson MH; Villa NY; Jaye DL; Nooka AK; Duffy A; McCachren SS; Manalo J; Switchenko JM; Barnes S; Potdar S; Azeem MI; Horvat AA; Parihar VC; Gong J; Liang Y; Smith GH; Gupta VA; Boise LH; Kaufman JL; Hofmeister CC; Joseph NS; Lonial S; Dhodapkar KM; Dhodapkar MV
    J Clin Invest; 2023 Aug; 133(15):. PubMed ID: 37526080
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Non-invasive imaging provides spatiotemporal information on disease progression and response to therapy in a murine model of multiple myeloma.
    Riedel SS; Mottok A; Brede C; Bäuerlein CA; Jordán Garrote AL; Ritz M; Mattenheimer K; Rosenwald A; Einsele H; Bogen B; Beilhack A
    PLoS One; 2012; 7(12):e52398. PubMed ID: 23300660
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The progression from MGUS to smoldering myeloma and eventually to multiple myeloma involves a clonal expansion of genetically abnormal plasma cells.
    López-Corral L; Gutiérrez NC; Vidriales MB; Mateos MV; Rasillo A; García-Sanz R; Paiva B; San Miguel JF
    Clin Cancer Res; 2011 Apr; 17(7):1692-700. PubMed ID: 21325290
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pathogenesis of myeloma.
    Anderson KC; Carrasco RD
    Annu Rev Pathol; 2011; 6():249-74. PubMed ID: 21261519
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Circulating Myeloid Derived Suppressor Cells (MDSC) That Accumulate in Premalignancy Share Phenotypic and Functional Characteristics With MDSC in Cancer.
    Ma P; Beatty PL; McKolanis J; Brand R; Schoen RE; Finn OJ
    Front Immunol; 2019; 10():1401. PubMed ID: 31275327
    [TBL] [Abstract][Full Text] [Related]  

  • 9. From MGUS to Multiple Myeloma, a Paradigm for Clonal Evolution of Premalignant Cells.
    van Nieuwenhuijzen N; Spaan I; Raymakers R; Peperzak V
    Cancer Res; 2018 May; 78(10):2449-2456. PubMed ID: 29703720
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Active multiple myeloma suppresses and typically eliminates coexisting MGUS.
    Campbell JP; Heaney JLJ; Pandya S; Afzal Z; Kaiser M; Owen R; Child JA; Gregory W; Morgan GJ; Jackson GH; Bunce CM; Drayson MT
    Br J Cancer; 2017 Sep; 117(6):835-839. PubMed ID: 28728165
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bone marrow transplantation generates T cell-dependent control of myeloma in mice.
    Vuckovic S; Minnie SA; Smith D; Gartlan KH; Watkins TS; Markey KA; Mukhopadhyay P; Guillerey C; Kuns RD; Locke KR; Pritchard AL; Johansson PA; Varelias A; Zhang P; Huntington ND; Waddell N; Chesi M; Miles JJ; Smyth MJ; Hill GR
    J Clin Invest; 2019 Jan; 129(1):106-121. PubMed ID: 30300141
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Synergistic Antimyeloma Activity of Dendritic Cells and Pomalidomide in a Murine Myeloma Model.
    Vo MC; Yang S; Jung SH; Chu TH; Lee HJ; Lakshmi TJ; Park HS; Kim HJ; Lee JJ
    Front Immunol; 2018; 9():1798. PubMed ID: 30123221
    [TBL] [Abstract][Full Text] [Related]  

  • 13. T cells in multiple myeloma display features of exhaustion and senescence at the tumor site.
    Zelle-Rieser C; Thangavadivel S; Biedermann R; Brunner A; Stoitzner P; Willenbacher E; Greil R; Jöhrer K
    J Hematol Oncol; 2016 Nov; 9(1):116. PubMed ID: 27809856
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Vigorous premalignancy-specific effector T cell response in the bone marrow of patients with monoclonal gammopathy.
    Dhodapkar MV; Krasovsky J; Osman K; Geller MD
    J Exp Med; 2003 Dec; 198(11):1753-7. PubMed ID: 14638846
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Accessory cells of the microenvironment protect multiple myeloma from T-cell cytotoxicity through cell adhesion-mediated immune resistance.
    de Haart SJ; van de Donk NW; Minnema MC; Huang JH; Aarts-Riemens T; Bovenschen N; Yuan H; Groen RW; McMillin DW; Jakubikova J; Lokhorst HM; Martens AC; Mitsiades CS; Mutis T
    Clin Cancer Res; 2013 Oct; 19(20):5591-601. PubMed ID: 24004671
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Replication pattern in cancer: asynchronous replication in multiple myeloma and in monoclonal gammopathy.
    Amiel A; Kirgner I; Gaber E; Manor Y; Fejgin M; Lishner M
    Cancer Genet Cytogenet; 1999 Jan; 108(1):32-7. PubMed ID: 9973921
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Establishment of a murine graft-versus-myeloma model using allogeneic stem cell transplantation.
    Binsfeld M; Beguin Y; Belle L; Otjacques E; Hannon M; Briquet A; Heusschen R; Drion P; Zilberberg J; Bogen B; Baron F; Caers J
    PLoS One; 2014; 9(11):e113764. PubMed ID: 25415267
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Plasma cell labeling index in the evaluation of smoldering (asymptomatic) multiple myeloma.
    Madan S; Kyle RA; Greipp PR
    Mayo Clin Proc; 2010 Mar; 85(3):300. PubMed ID: 20194156
    [No Abstract]   [Full Text] [Related]  

  • 19. Treg and Oligoclonal Expansion of Terminal Effector CD8
    Joshua DE; Vuckovic S; Favaloro J; Lau KHA; Yang S; Bryant CE; Gibson J; Ho PJ
    Front Immunol; 2021; 12():620596. PubMed ID: 33708212
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cell autonomous and microenvironmental regulation of tumor progression in precursor states of multiple myeloma.
    Manier S; Kawano Y; Bianchi G; Roccaro AM; Ghobrial IM
    Curr Opin Hematol; 2016 Jul; 23(4):426-33. PubMed ID: 27101529
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.